Pegylated Interferon-α2a Inhibits Proliferation of Human Liver Cancer Cells In Vitro and In Vivo

Hironori Kusano*1, Jun Akiba1, Sachiko Ogasawara1, Sakiko Sanada1, Makiko Yasumoto1, Masamichi Nakayama1, Keiko Ueda1, Kosuke Ueda1, Takashi Kurita1, Keita Todoroki1, Yumi Umeno1, Osamu Nakashima2, Hirohisa Yano1

1 Department of Pathology, Kurume University School of Medicine, Kurume, Fukuoka, Japan, 2 Department of Clinical Laboratory Medicine, Kurume University Hospital, Kurume, Fukuoka, Japan

Abstract

Purpose: We investigated the effects of pegylated interferon-α2a (PEG-IFN-α2a) on the growth of human liver cancer cells.

Methods: The effect of PEG-IFN-α2a on the proliferation of 13 liver cancer cell lines was investigated in vitro. Cells were cultured with medium containing 0–4,194 ng/mL of PEG-IFN-α2a, and after 1, 2, 3, or 4 days of culture, morphologic observation and growth assay were performed. After hepatocellular carcinoma (HCC) cells (HAK-1B and KIM-1) were transplanted into nude mice, various doses of PEG-IFN-α2a were subcutaneously administered to the mice once a week for 2 weeks, and tumor volume, weight, and histology were examined.

Results: PEG-IFN-α2a inhibited the growth of 8 and 11 cell lines in a time- and dose-dependent manner, respectively, although the 50% growth inhibitory concentrations of 7 measurable cell lines on Day 4 were relatively high and ranged from 253 ng/mL to 4,431 ng/mL. Various levels of apoptosis induction were confirmed in 8 cell lines. PEG-IFN-α2a induced a dose-dependent decrease in tumor volume and weight, and a significant increase of apoptotic cells in the tumor. Subcutaneous administration of clinical dose for chronic hepatitis C (3 μg/kg, 0.06 μg/mouse) was effective and induced about 30-50% reduction in the tumor volume and weight as compared with the control.

Conclusions: Although in vitro anti-proliferative effects of PEG-IFN-α2a were relatively weak, PEG-IFN-α2a induced strong anti-tumor effects on HCC cells in vivo. The data suggest potential clinical application of PEG-IFN-α2a for the prevention and treatment of HCC.

Introduction

Interferons (IFNs) are types of cytokine that are produced by host cells, such as leukocytes, in response to inflammation. Since IFNs possess antiviral activity, antiproliferative activity and various immunoregulatory activities, IFN therapy is used to treat patients with chronic viral hepatitis or certain types of cancer including malignant melanoma, acquired immunodeficiency syndrome-related Kaposi’s sarcoma and some hematopoietic malignancies [1,2]. Lai et al also showed that recombinant IFNs is useful in prolonging survival among patients with inoperable hepatocellular carcinoma (HCC) [3]. In addition, some studies showed IFN therapy might prevent either occurrence or recurrence after initial curative therapy of HCC, such as liver resection and radiofrequency ablation, in patient with chronic viral hepatitis [4–7]. This cancer preventive effect of IFNs is regarded mainly as results of their antiviral effect and the consequent suppression of inflammation, and might be due to their direct antitumor effect against clinically undetectable HCC as well. The detailed mechanism of the antitumor effect of IFNs, however, remains obscure.

Pegylated interferon-α2a (PEG-IFN-α2a) and pegylated interferon-α2b (PEG-IFN-α2b), which are used to treat patients with chronic hepatitis C virus (HCV) or B virus (HBV) infection, are modified IFNs that have longer serum half-life in body than non-pegylated forms of IFNs, therefore they can be given to...
patients only once a week, whereas a standard IFN without pegylation used to be injected up to three to five times a week. This once-a-week injection of pegylated IFNs in combination with daily oral dosing of the nucleoside analogue ribavirin has substantially improved the rate of sustained virological response in patients with chronic HCV infection and got a position as the first line therapy [8,9]. We previously reported that PEG-IFN-α2b which contains 12 kDa polyethylene glycol (PEG) has stronger antitumor effects in vivo than non-pegylated IFNs and this result might be indicating that continuous IFNs exposure to cancer cells in body is more effective than continual injection [10]. On the basis of above-described background, we examined the growth inhibitory effects of PEG-IFN-α2a which contains two chains of 20 kDa PEG and has the longest serum half-life among clinically available IFNs on liver cancer cell lines in vitro and in vivo.

Methods

Cell Lines and Cell Culture

This study used 11 HCC cell lines (KIM-1, KYN-1, KYN-2, KYN-3, HAK-1A, HAK-1B, HAK-2, HAK-3, HAK-4, HAK-5, and HAK-6) and 2 human combined hepatocellular and cholangiocarcinoma (CHC) cell lines (KMCH-1 and KMCH-2). These HCC and CHC cell lines were originally established in our laboratory, and each cell line retains the morphological and functional features of the original tumor as described elsewhere [11–20]. Since tumorigenicity is higher in HAK-1B and KIM-1 cells than in the other 11 cell lines that we have, we used these two cell lines for in vivo study.

The cells were grown in Dulbecco’s Modified Eagle Medium (Nissui Sefyaku, Co., Japan) supplemented with 2.5% heat-inactivated (56°C, 30 min) fetal bovine serum (FBS, Bioserum, Victoria, Australia), 100 U/mL penicillin, 100 µg/mL streptomycin (GIBCO BRL/Life Technologies, Inc., Gaithersburg, MD) and 12 mmol/L sodium bicarbonate, in a humidified atmosphere of 5% CO₂ in air at 37°C.

IFN and Reagents

PEG-IFN-α2a (PEGASYS®, Chugai Pharmaceutical Co., Ltd., Tokyo, Japan) with the specific activity of 1.4 X 10⁷ IU/mg protein and non-pegylated IFN-α2a (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) with that of 2.0 X 10⁶ IU/mg protein were used in the study. Anti-bromodeoxyuridine (BrdU) antibody and fluorescein isothiocyanate-conjugated goat anti-mouse immunoglobulin (FITC-GAM) were purchased from Becton Dickinson Immunocytometry Systems USA (San Jose, CA); control normal mouse IgG₁, from DAKO (Gloustrup, Denmark); rat antibody against mouse endothelial cells (anti-CD34, clone MEC14.7), from Serotec Co., UK; and mouse monoclonal antibody against human α-smooth muscle actin (SMA) that cross-reacts with mouse α-SMA (clone 1A4).

Effects of PEG-IFN-α2a on the Proliferation of HCC and CHC Cell Lines in vitro

The effects of PEG-IFN-α2a on the growth of the cultured cells were examined with colorimetry using 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyl tetrazolium bromide (MTT) assay kits (Chemicon, Temecula, CA) as described elsewhere [18,21]. Briefly, the cells (1.5~8 X 10⁵ cells per well) were seeded on 96-well plates (Nunc, Inc, Roskilde, Denmark), cultured for 24 hours, and the culture medium was changed to a new medium with or without PEG-IFN-α2a (0.016, 0.064, 0.256, 1.024, 4.096, 16.4, 65.5, 262, 1,048, or 4,194 ng/mL). After culturing for 24, 48, 72 or 96 hours, the number of viable cells was measured with ImmunoMini NJ-2300 (Naige Nunc International, Tokyo, Japan) by setting the test wavelength at 570 nm and the reference wavelength at 630 nm. To keep the optical density within linear range, all experiments were performed while the cells were in the logarithmic growth phase.

Quantitative analysis of apoptotic cells induced by PEG-IFN-α2a

HAK-1B or KIM-1 cells cultured with medium alone (control), non-pegylated IFN-α2a (10 ng/ml=2,000 IU/ml) or PEG-IFN-α2a (144 ng/ml=2,000 IU/ml) for 72 hours were stained with the Annexin V-EGFP (enhanced green fluorescent protein) Apoptosis Detection Kits (Medical & Biological Laboratories Co., Ltd.) according to the manufacturer’s instructions. After staining, the cells were analyzed using a FACScan (Becton Dickinson Immunocytometry Systems, San Jose, CA), and Annexin V-EGFP-positive apoptotic cell rate was determined.

Morphological Observation

For morphological observation under a light microscope, cultured cells were seeded on Lab-Tek tissue culture chamber slides (Nunc, Inc.), cultured with or without PEG-IFN-α2a (262, 1,048 or 4,194 ng/mL) for 72 hours, fixed for 10 min in Carnoy’s solution, and stained with hematoxylin-eosine (HE).

Effects of PEG-IFN-α2a on HCC Cell Proliferation in Nude Mice

All animal experiments were approved by the institutional committee for animal experiments in Kurume University School of Medicine (Permit Number: 1334), and conducted according to the Guide for the Care and Use of Laboratory Animals of the National Institute of Health and the Regulations for Animal Experimentation of Kurume University School of Medicine. Mice were killed by cervical dislocation under diethyl ether anesthesia, and all efforts were made to minimize suffering. Cultured HAK-1B or KIM-1 (10⁵ cells/mouse) was subcutaneously (s.c.) injected into the backs of 5-week-old female BALB/c athymic nude mice (Clea Japan, Inc., Osaka, Japan). Five to seven days later when the largest diameter of the tumor, which was measured by using caliper, reached approximately 5~10 mm (Day 0), tumor volume (mm³) was calculated in the equation ‘the largest diameter X (the smallest diameter)² X 0.5’, and then the mice were divided into 5 groups (n=8 each). Tumor volume was measured on Day 0, 1, 2, 4, 6, 8, 10, 12, and 14. Mouse body weight was measured on Day 0.
8, and 14. After 2-week treatment, mice were killed on Day 15 and the actual tumor weight was also measured. In experiment 1, the 5 groups of 8 mice received either phosphate-buffered saline (PBS) (Control) or PBS with the different dosages of PEG-IFN-α2a (0.06–60 µg) once a week for 2 consecutive weeks (Day 1 and Day 8). The clinical dose of PEG-IFN-α2a in chronic hepatitis C treatment is about 3 µg/kg and is equivalent to the lowest dose (0.06 µg/mouse=840 IU/mouse) in this experiment. After killing, resected tumors were used for morphological studies (e.g., HE staining and immunohistochemistry) and Enzyme-linked immunosorbent assay (ELISA) analysis. Every mouse received an intraperitoneal injection of 1 mg of BrdU 30 min before killing.

In experiment 2, to examine the difference between non-pegylated and pegylated IFNs, 5 groups of 8 mice received either PBS (Control), PBS with 0.0042 or 0.042 µg of IFN-α2a (840 or 8,400 IU, respectively), or PBS with 0.06 or 0.6 µg of PEG-IFN-α2a (840 or 8,400 IU, respectively). In this experiment, tumor weights on Day 15 and numbers of apoptotic cells were compared among the groups.

Morphological Examination of the Subcutaneous Tumors of Nude Mice

The number of cells showing the characteristics of apoptosis (e.g., cytoplasmic shrinkage, chromatin condensation, and nuclear fragmentation) was counted in at least three 0.25 mm²-areas within an HE-stained specimen, and the average number per area was obtained. The TUNEL technique (ApopTag® Peroxidase In Situ apoptosis Detection Kits, CHEMICON International, Inc, CA) was used to detect apoptotic cells, and the average number of TUNEL-positive cells per area was obtained, as described above. The specimens were also immunostained for incorporated BrdU using BrdU Staining Kits (Nichirei, Tokyo, Japan), and HistoMouse™-plus kits to detect antibody, Histofine simple stain mouse MAX-PO (Rat) kits (Nichirei, Tokyo, Japan), and HistoMouse™-plus kits to detect artery-like blood vessels as described in our previous report [21,22]. The number of double-immunostaining-positive blood vessels in the tumor was counted on each specimen. Granulation tissue within the tumor were excluded in counting of blood vessels. The size of the counted area was measured by tracing the outline displayed on a computer monitor using Mac SCOPE (MITANI Corp., Chiba, Japan). From the obtained number of vessels per unit area (mm²), the group mean was obtained for group comparison.

Enzyme-linked immunosorbent assay (ELISA)

Portions of the resected xenograft tumors were homogenized in 500 µl of ice-cold Ca²⁺ and Mg²⁺-free PBS containing 100 mg/ml phenylmethylsulfonyl fluoride using a pellet pestle. The mixture was centrifuged for 10 min (12,000 g, 4°C), and the supernatant was stored at -20°C until use. After the determination of the amount of the tissue protein in the supernatant using a BCA protein assay reagent (Pierce, Rockford, IL), the amount of basic fibroblast growth factor (bFGF) and IL-8 was measured by using commercially available ELISA kits (R&D Systems, Minneapolis, MN).

Statistics

Comparisons of estimated tumor volume and colorimetric cell growth were performed using two-factor factorial ANOVA and Student’s t-test, respectively. The other data comparisons were performed using the Mann-Whitney U test.

Results

Effects of PEG-IFN-α2a on Liver Cancer Cell Proliferation in vitro

Twenty-four hours after the addition of 4,194 ng/mL of PEG-IFN-α2a, mild increase in the relative viable cell number occurred in 9 cell lines (all cell lines except KYN-2, HAK-1A, HAK-6, and KMCH-1). However, after 72 hours or later, a 10% or more decrease in the cell number occurred in all cell lines (Figure 1A). In HAK-2, HAK-3, and HAK-4, proliferation was suppressed up to 72 hours and the cell number reached a plateau or slightly increased thereafter. In the other 8 cell lines, proliferation was suppressed to varying degrees up to 96 hours.

The relative viable cell number was suppressed in 11 cell lines (all cell lines except HAK-1A and KMCH-2) in a dose-dependent manner after the 96 hours-incubation with PEG-IFN-α2a (Figure 1B). In 7 cell lines (HAK-1B, KMCH-1, KIM-1, KYN-1, HAK-6, KYN-3, and KYN-2), the number was suppressed to 50% or less with 4,194 ng/mL of PEG-IFN-α2a, and the 50% inhibitory concentration (IC50) was 253 ng/mL for HAK-1B, 670 ng/mL for KMCH-1, 1,105 ng/mL for KIM-1, 1,128 ng/mL for KYN-1, 1,302 ng/mL for HAK-6, 1,524 ng/mL for KYN-3, and 4,431 ng/mL for KYN-2. No relationship was detected between the histological differentiation level of the original tumor and sensitivity to the anti-proliferative effect of PEG-IFN-α2a.

Seventy-two hours after adding 4,194 ng/mL of PEG-IFN-α2a, 8 cell lines (all cell lines except KYN-3, HAK-1A, HAK-2, HAK-3, and KMCH-2) showed characteristics of apoptosis, e.g., cytoplasmic shrinkage, chromatin condensation, and nuclear fragmentation, in various degrees and in a dose-dependent manner (Figure 2). The appearance of apoptosis was further confirmed in HAK-1B and KM-1 cells cultured with 10 ng/ml (=2,000 IU/ml) of IFN-α2a and 144 ng/ml (=2,000 IU/ml) of PEG-IFN-α2a by apoptosis detection assay (Table 1). Non-pegylated IFN-α2a induced much more apoptosis than PEG-IFN-α2a.

Effects of PEG-IFN-α2a on HCC Cell Proliferation in Nude Mice

Chronological changes in estimated tumor volume after subcutaneous injection of cultured HAK-1B or KIM-1 cells to nude mice are summarized in Figure 3. Dose-dependent suppression of tumor volume was observed in mice receiving PEG-IFN-α2a. In the experiment of HAK-1B tumors, a significant difference in the changes in tumor volume and tumor weight was observed between the Control mice and the mice
Figure 1. Anti-proliferative effect of PEG-IFN-α2a. (A) Chronological changes in relative viable cell number (% of the control) after adding 4,194 ng/mL of PEG-IFN-α2a. Growth was suppressed with time in 8 cell lines. (B) 96 hours after adding 10 different concentrations of PEG-IFN-α2a. Cell proliferation was suppressed in a dose-dependent manner in 11 cell lines. The suppression was significant ($P < 0.0001$~$0.05$) in the ranges of $0.016$~$4,194$ ng/mL of PEG-IFN-α2a in HAK-6, $0.256$~$4,194$ ng/mL in KYN-3 and HAK-1A, $4.096$~$4,194$ ng/mL in KIM-1, KYN-1, HAK-1B, HAK-2 and KMCH-2, $16.4$~$4,194$ ng/mL in KYN-2, HAK-5 and KMCH-1, $262$~$4,194$ ng/mL in HAK-4, and at $4,194$ ng/mL in HAK-3 (Student $t$-test). Eight samples were used in each experiment ($n = 8$). The experiment was repeated at least 3 times for each cell line. The figures represent average ± SE of the experiments.

doi: 10.1371/journal.pone.0083195.g001

Figure 2. Photomicrograph of HAK-1B cells cultured for 72 hours on a Lab-Tek Chamber slide. (A) Without PEG-IFN-α2a in culture medium. (B) With 4,194 ng/mL of PEG-IFN-α2a in culture medium. Apoptotic cells (short arrows) characterized by cytoplasmic shrinkage, chromatic condensation and nuclear fragmentation were noted (HE staining, X 200).

doi: 10.1371/journal.pone.0083195.g002
that received 0.06, 0.6, 6 or 60 μg of PEG-IFN-α2a (P < 0.0001 by two-factor factorial ANOVA; and P < 0.001–0.02 by the Mann-Whitney U test, Figure 3A and Table 2). In the experiment of KIM-1 tumors, a significant reduction of tumor volume was also observed with the use of PEG-IFN-α2a (P < 0.001 by two-factor factorial ANOVA, Figure 3B). There were significant differences in the actual tumor weight between the Control group and the PEG-IFN-α2a groups, except for the PEG-IFN-α2a (0.06 μg) group (Table 2). The actual tumor weight at the end of the experiment 2 was summarized in Table 3. Subcutaneous injection of 0.6 μg of PEG-IFN-α2a induced the significant reduction of tumor weight, compared with the Control group and the group that received the same international unit of non-pegylated IFN-α2a (P<0.005 and P<0.03, respectively). In this experiment, there was no significant difference between the Control group and the PEG-IFN-α2a (0.06 μg) group (P=0.078).

Histological examination of the HAK-1B tumor specimens stained with HE revealed that the numbers of apoptotic cells in the mice treated with PEG-IFN-α2a (0.06 or 0.6 μg) were significantly higher than that of the Control, and the number increased dose dependently (Figure 4, A and B; Table 4). The incidence of apoptosis in TUNEL-stained sections showed the same tendencies as those obtained in HE-stained sections (Figure 4C and Table 4). Immunohistochemical examination of BrdU uptake in HAK-1B tumors revealed that there was no significant difference in BrdU labeling index between the Control and PEG-IFN-α2a (0.06 or 0.6 μg) groups (Table 4). As for apoptosis, similar findings were observed in experiment 2 in which KIM-1 was used. The group treated with 0.6 μg of PEG-IFN-α2a showed increased number of apoptotic cells than the control group. There was no significant difference between the control and IFN-α2a group. In addition, the group treated with

Table 1. Quantitative analysis of apoptosis in HAK-1B or KIM-1.

| Cell line | Annexin V-EGFP apoptotic cells (%) | IFN-α2a | PEG-IFN-α2a |
|-----------|-----------------------------------|---------|-------------|
| HAK-1B    | 4.1 ± 0.5P                        | 18.5 ± 0.3 | 10.9 ± 0.5  |
| KIM-1     | 9.4 ± 0.4                          | 47.0 ± 0.2 | 29.8 ± 2.1  |

*a Cells were cultured with medium alone (Control), IFN-α2a (10 ng/ml=2,000 IU/ml) or PEG-IFN-α2a (144 ng/ml=2,000 IU/ml). b Mean ±SE.

doi: 10.1371/journal.pone.0083195.t001

Figure 3. Time-course change in estimated tumor volumes of subcutaneously transplanted HAK-1B (A) or KIM-1 (B) tumors in nude mice in Experiment 1. The mice received a subcutaneous injection of 0.06 (▲), 0.6 (○), 6 (●), or 60 (∆) µg of PEG-IFN-α2a, or medium alone (Control) (□), once a week for 2 consecutive weeks. The arrows show the days of injection. The figures represent average ± SE. *P < 0.0001, versus the other groups. †P < 0.01, versus the other groups.

doi: 10.1371/journal.pone.0083195.g003

PEG-IFN-α2a Inhibits HCC Growth

PLOS ONE | www.plosone.org
December 2013 | Volume 8 | Issue 12 | e83195
Table 2. The weight of subcutaneous tumors of HAK-1B or KIM-1 cells in nude mice at killing (Experiment 1).

| Treatment groupa | Tumor weight (g) |
|------------------|------------------|
|                  | HAK-1B           | KIM-1            |
| Control          | 0.303 ± 0.058     | 1.050 ± 0.247    |
| PEG-INF-α2a (0.06 µg) | 0.141 ± 0.032 | 0.725 ± 0.172    |
| PEG-INF-α2a (0.6 µg) | 0.033 ± 0.01   | 0.439 ± 0.04     |
| PEG-INF-α2a (6 µg) | 0.015 ± 0.01    | 0.434 ± 0.04     |
| PEG-INF-α2a (60 µg) | 0.030 ± 0.05   | 0.076 ± 0.05     |

a Cultured HAK-1B or KIM-1 cells (1.0 X 10^7) were subcutaneously transplanted into nude mice. Five groups of 8 mice received either phosphate-buffered saline (PBS) (Control) or PBS with the different dosages of PEG-INF-α2a (0.06–60 µg) once a week. All mice were killed and the tumor weight was measured on the 15th day. Mean ± SE. b P < 0.02, versus the PEG-INF-α2a (0.06 µg) group; c P < 0.01, versus the PEG-INF-α2a (0.6 µg) group; d P < 0.01, versus the PEG-INF-α2a (6 µg) group; e P < 0.02, versus PEG-INF-α2a (60 µg). f Not significant, versus the PEG-INF-α2a (0.06 µg) group; P < 0.03, versus the PEG-INF-α2a (0.6 µg) group; P < 0.05, versus the PEG-INF-α2a (6 µg) group; g P < 0.01, versus the PEG-INF-α2a (0.6 µg) group; h P < 0.001, versus the PEG-INF-α2a (60 µg) group.

doi: 10.1371/journal.pone.0083195.t002

Table 3. The actual weight and numbers of apoptotic cells of subcutaneous tumors at killing (Experiment 2).

| Treatment groupa | activity of interferon (IU) | Tumor weight (g) | Apoptosis (Number of cells/0.25mm²) |
|------------------|-----------------------------|------------------|-------------------------------------|
| Control          | 0 IU                        | 0.726 ± 0.098 b  | 7.6 ± 0.9a                          |
| INF-α2a (0.004 µg) | 840 IU                      | 0.588 ± 0.072 d  | 7.9 ± 0.9a                          |
| INF-α2a (0.042 µg) | 8,400 IU                    | 0.531 ± 0.046 b  | 7.6 ± 0.7b                          |
| PEG-INF-α2a (0.06 µg) | 840 IU                    | 0.493 ± 0.04 b  | 8.9 ± 0.9                          |
| PEG-INF-α2a (0.6 µg) | 8,400 IU                    | 0.355 ± 0.03    | 9.7 ± 1.0b                          |

a Cultured HAK-1B cells (1.0 X 10⁷) were subcutaneously transplanted into nude mice. Five groups of 8 mice received either PBS (Control), PBS with 0.0042 or 0.042 µg of INF-α2a (840 or 8,400 IU, respectively), or PBS with 0.06 or 0.6 µg of PEG-INF-α2a (840 or 8,400 IU, respectively). All mice were killed and the tumor weight was measured on the 15th day. The number of apoptotic cells was counted in at least three 0.25 mm²-areas in each section stained with hematoxylin and eosin, and the average number per area in each group was obtained. Mean ± SE. b P < 0.05, versus the PEG-INF-α2a (0.6 µg) group. c P < 0.02, versus the PEG-INF-α2a (0.6 µg) group. d P < 0.02, versus the PEG-INF-α2a (0.6 µg) group. e P < 0.03, versus the PEG-INF-α2a (0.6 µg) group. f P < 0.02, versus the PEG-INF-α2a (0.6 µg) group. g P < 0.05, versus the PEG-INF-α2a (0.6 µg) group. h P < 0.001, versus the PEG-INF-α2a (0.6 µg) group.

doi: 10.1371/journal.pone.0083195.t003
mechanisms other than apoptosis, which affect the sensitivity to antitumor effects of PEG-IFN-α2a. We previously reported that both pegylated and non-pegylated IFN-α inhibited the proliferation of cultured HCC cells by inducing the cell-cycle arrest [10,18]. The expression of interferon receptor on tumor cells might be a possible factor related to antitumor effect. For instance, Nagano et al reported that the expression of this type I IFN receptor on HCC tissue might be a useful predictor to find potential responder to INF-α/5-fluorouracil combination therapy [25]. Immunomodulation by IFNs has also been well studied as a factor related to antitumor effect. In this study, we used athymic mice, which lack mature T-cell, and human IFNs. Since IFNs are species-specific [26], we surmise that this immunomodulatory effect is limited in our study, but this should be confirmed in the future study using mouse IFN.

Morphological observation of the subcutaneous tumors of nude mice revealed that s.c. injection of PEG-IFN-α2a induce the significant increase of apoptotic cells compared with Control group. This result in the in vivo study is consistent with that in the in vitro study showing characteristic changes of apoptosis after adding PEG-IFN-α2a. Although the inhibition of angiogenesis as well as the induction of apoptosis is regarded as one of the biological effects of IFNs, there was no significant difference in the number of artery-like blood vessels of the subcutaneous tumors between the control and treatment groups. There are two possible explanations of this finding. Firstly, PEG-IFN-α2a was less effective for mouse endothelial cells compared with human cancer cells due to the species specificity of human IFNs. Secondly, it might be difficult to visualize the alteration in the number of vessels in order to examine the efficacy of drugs that possess antiangiogenic

---

**Table 4. Numbers of apoptotic cells and BrdU-positive cells in human HCC tumors subcutaneously transplanted in nude mice.**

| Treatment group | Apoptosis (Number of cells/0.25mm²) | BrdU Labeling Index (Number of positive cells/0.25mm²) |
|-----------------|-------------------------------------|-----------------------------------------------------|
|                 | HE stain                            | TUNEL method                                        |
| Control         | 8.4 ± 0.8₄,₆,aría                    | 9.6 ± 1.1ᵡ                                          | 32.3 ± 1.₆SBATCH |
| PEG-IFN-α2a (0.06 μg) | 12.2 ± 1.₇₄ | 15.₄ ± 1.₈₄ | 27.₀ ± 2.₆ |
| PEG-IFN-α2a (0.6 μg) | 12.₄ ± 0.₉₄ | 1₆.₁ ± 1.₅₄ | 3₁.₃ ± 6.₉ |

a Cultured HAK-1B cells (1.₀ X 1₀⁷) were subcutaneously transplanted into nude mice. Five groups of 8 mice received either phosphate-buffered saline (PBS) (Control) or PBS with the different dosages of PEG-IFN-α2a (0.06–60 μg) once a week. Tumors of mice that received 6 or 60 μg of PEG-IFN-α2a could not be used because the tumors were too small to evaluate. All mice were killed on the 15th day. b The number of apoptotic cells was counted in at least three 0.25 mm²-areas in each section stained with hematoxylin and eosin, and the average number per area in each group was obtained. The number of TUNEL-positive cells was also counted in the same manner. c The number of BrdU-positive cells was counted in at least three 0.25 mm²-areas in each section, and the average number per area in each group was obtained as the labeling index. d Mean ± SE. e P < 0.02, versus the other groups. f Not significant, versus the other groups.

---

**Figure 4. Photomicrograph of subcutaneous human HCC tumor in nude mice that was developed after the injection of HAK-1B cells.** (A) A control mouse that received culture medium alone. The tumor shows a compact arrangement of tumor cells and a sinusoid-like structure in the stroma. (B) A mouse that received a s.c. injection of 0.06 μg of PEG-IFN-α2a. There are some apoptotic tumor-cells characterized by shrinkage and eosinophilic change in the cytoplasm, chromatin condensation and/or fragmentation of nuclei (arrows, HE staining, X200). (C) The same tumor as shown in (B). There are some TUNEL-positive cells showing brown nuclei (arrows, stained by the TUNEL technique, X200).
activity. Hlatky et al explained in their review article that the reason is that the tightness of the coupling between vessel drop-out and tumor-cell drop-out after the treatment is different [27]. We had observed similar findings in our previous report in which human HCC tumors subcutaneously transplanted in nude mice showed much apoptosis in either PEG-IFN-α2b or IFN-α2b treatment group compared with the Control group, but no significant difference in the number of blood vessels [10]. Kojiro et al also showed that s.c. injection of BALL-1 lymphoblastoid IFN-α increase the number of artery-like blood vessels and the protein expression of bFGF within HCC xenograft tumors in spite of the significant decrease of actual tumor weight [28]. In contrast, Dinney et al showed that IFN-α2a decreases the blood vessel density and the expression of bFGF in orthotopic xenograft model of bladder tumor [29]. The reason for these contrary findings remains unclear and further evaluation with caution is needed by using different doses and types of IFNs and different cell lines, not only in subcutaneous tumor model but also in orthotopic model.

The association between IFN therapy and occurrence or recurrence of HCC has been investigated in some reports. HALT-C trial group showed in their randomized control trial in a large cohort that long-term PEG-IFN-α2a therapy does not reduce the incidence of HCC among patients with chronic HCV infection who have previously failed to achieve a sustained virologic response to therapy [30]. Among only patients with cirrhosis, long-term PEG-IFN-α2a therapy reduced a risk of HCC after a long-time observation [31]. EPIC study group also showed long-term PEG-IFN-α2b therapy does not prevent HCC [32]. On the other hand, Nishiguchi et al reported that long-term IFN-α therapy after curative resection of HCV-related HCC prolongs the survival rate, although preventative effect of intrahepatic recurrence was marginal [33]. Sakaguchi et al also showed that among patients who underwent radical

Figure 5. Photomicrograph of resected HAK-1B tumor. (A) Tumor cells are replaced with large granulation tissue at the middle of resected tumor. (arrowheads, HE staining, X20). (B) Artery-like blood vessels in the tumor (arrow, HE staining, X200). (C) Artery-like blood vessel in the tumor (arrow, CD34/α-SMA double-immunostain, X200).

doi: 10.1371/journal.pone.0083195.g005

Table 5. Numbers of artery-like blood vessels, and Enzyme-linked immunosorbent assay (ELISA) of angiogenesis factors in human HCC tumors subcutaneously transplanted in nude mice.

| Treatment group | Artery-like blood vesselb (Number of vessels/mm2) | Levels in the tumor lysatec (pg/40 μg cellular protein) |
|-----------------|-----------------------------------------------|-------------------------------------------------------|
|                 | Inside of tumor                               | bFGF                                    | IL-8                                    |
| Control         | 0.104 ± 0.02d,e                               | 14.0 ± 1.8e                              | 2.8 ± 1.0e                              |
| PEG-IFN-α2a (0.06 μg) | 0.194 ± 0.05                               | 19.8 ± 2.1                              | 4.9 ± 1.3                              |

a Cultured HAK-1B cells (1.0 X 107) were subcutaneously transplanted into nude mice. Five groups of 8 mice received either phosphate-buffered saline (PBS) (Control) or PBS with the different dosages of PEG-IFN-α2a (0.06–60 μg) once a week. Tumors of mice that received 0.6, 6 or 60 μg of PEG-IFN-α2a could not be used because the tumors were too small to evaluate. All mice were killed on the 15th day. b The number of artery-like blood vessels within tumor was counted on each section, and the average number per area in each group was obtained. c The expression levels of basic fibroblast growth factor (bFGF) and IL-8 of the resected tumors were measured by ELISA. d Mean ± SE. e Not significant, versus the PEG-IFN-α2a (0.06 μg) group.

doi: 10.1371/journal.pone.0083195.t005
radiofrequency therapy for HCV-related HCC, long-term IFN-α2b therapy reduced the recurrent rate of HCC [4]. These reports with conflicting results may be suggesting that IFN therapy is effective only after the initial curative treatment of HCV-related HCC. In addition, there are several reports that support that IFN therapy prevents the development of HCC among patients with chronic HBV infection or those underwent curative resection of HBV-related HCC [5,7]. Thus the chemopreventive effect of IFNs against HCC are still controversial, and mechanisms behind that remain unclear. Antiviral effect against HBV and HCV, which are risk factors for HCC, and immunomodulatory effect of IFNs are regarded as main mechanisms. Another possible mechanism is that IFNs may suppress the growth of clinically undetectable HCC due to their direct antitumor effect. Our finding in the current study provide the evidence that PEG-IFN-α2a possesses the direct antitumor effect against HCC.

In conclusion, we demonstrated antitumor effect of PEG-IFN-α2a for human liver cancer cells in vitro and in vivo and our results suggest that longer contact to IFNs may induce stronger antitumor effect in body. PEG-IFN-α2a might be a possible treatment option for HCC as well as chronic viral hepatitis. Further studies are needed from both molecular and clinical viewpoint points in order to find out particular patient group those respond to this therapy.

Acknowledgements
We thank Ms. Akemi Fujiyoshi for her assistance in our experiments.

Author Contributions
Conceived and designed the experiments: HK JA SO ON HY. Performed the experiments: HK JA SO SS MY MN KU TK KT YU ON HY. Analyzed the data: HK JA SO SS MY MN KU TK KT YU ON HY. Contributed reagents/materials/analysis tools: HK JA SO SS MY MN KU TK KT YU ON HY. Wrote the manuscript: HK JA SO ON HY.

References
1. Pestka S, Langer JA, Zoon KC, Samuel CE (1987) Interferons and their actions. Annu Rev Biochem 56: 727–777. doi:10.1146/annurev.bi.56.070187.003455. PubMed: 2441659.
2. Jonasch E, Haluska FG (2001) Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist 6: 34–55. doi:10.1634/theoncologist.6-1-34. PubMed: 11161227.
3. Lai CL, Lau JY, Wu PC, Ngn H, Chung HT et al. (1993) Recombinant interferon-alpha in inoperable hepatocellular carcinoma: a randomized controlled trial. Hepatology 17: 389–394. doi:10.1002/hep.180170307. PubMed: 8338088.
4. Sakaguchi Y, Kudo M, Fukunaga T, Minami Y, Chung H et al. (2005) Low-dose, long-term, intermittent interferon-alpha-2b therapy after radical treatment by radiofrequency ablation delays clinical recurrence in patients with hepatitis C virus-related hepatocellular carcinoma. Intervirology 48: 64–70. doi:10.1159/000082097. PubMed: 15785902.
5. Miyake Y, Kobashi H, Yamamoto K (2009) Meta-analysis: the effect of interferon on development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Gastroenterol 44: 470–475. doi:10.1007/s00535-009-0024-z. PubMed: 19308310.
6. Miyake Y, Iwasa Y, Yamamoto K (2010) Meta-analysis: reduced incidence of hepatocellular carcinoma in patients not responding to interferon therapy of chronic hepatitis C. Int J Cancer 127: 989–996. PubMed: 19957327.
7. Qu LS, Jin F, Huang XW, Shen ZX (2010) Interferon-α therapy after curative resection prevents early recurrence and improves survival in patients with hepatitis B virus-related hepatocellular carcinoma. J Surg Oncol 102: 796–801. doi:10.1002/jso.21741. PubMed: 20886584.
8. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M et al. (2001) Peginterferon alpha-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C virus infection. N Engl J Med 347: 975–982. doi:10.1056/NEJMoa020047. PubMed: 12324553.
9. Fried MW, Shiffman ML, Reddy KR, Smith C, Mannos G et al. (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347: 975–982. doi:10.1056/NEJMoa020047. PubMed: 12324553.
10. Yano H, Ogasawara S, Momosaki S, Akiba H, Kojoj S et al. (2006) Growth inhibitory effects of pegylated IFN-α2b on human liver cancer cells in vitro and in vivo. Liver Int 26: 964–975. doi:10.1111/j.1478-3231.2006.01321.x. PubMed: 16958337.
11. Utsunomiya I, Iemura A, Yano H, Akiba H, Kojjoj M (1999) Establishment and characterization of a new human hepatocellular carcinoma cell line, HAK-3, and its response to growth factors. Int J Oncol 15: 669–675. PubMed: 10493497.
12. Murakami T (1984) Establishment and characterization of human hepatoma cell line (KIM-1). Acta Hepatob Gastroenterol Jpn 25: 532–539. doi:10.25975/kangoz.25.532.
13. Murakami T, Maruwi M, Fukuda K, Kojoj M, Tanaka M, et al. (1988) Characterization of a new human hepatoma cell line (KYN-3) derived from the ascites of the hepatoma patient [Abstract]. Jpn J Cancer Res 292 Proceedings of the Japanese Cancer Association.
14. Murakami T, Yano H, Maruiw M, Sugihara H, Kojoj M (1987) Establishment and characterization of a human combined hepatocellulargiobiliary carcinoma cell line and its heterologous transplantation in nude mice. Hepatology 7: 551–556. doi:10.1002/hep.180070322. PubMed: 3032760.
15. Haramaki M, Yano H, Iemura A, Momosaki S, Ogasawara S et al. (1997) A new human hepatocellular carcinoma cell line (HAK-2) forms various structures in collagen gel matrices. Hum Cell 10: 183–192. PubMed: 9436038.
16. Yano H, Iemura A, Fukuda K, Mizoguchi A, Haramaki M et al. (1993) Establishment of two distinct human hepatocellular carcinoma cell lines from a single nodule showing clonal dedifferentiation of cancer lines. Hepatology 18: 320–327. doi:10.1002/hep.10935920027. PubMed: 8393423.
17. Yano H, Iemura A, Haramaki M, Momosaki S, Ogasawara S et al. (1996) A new combined hepatocellular and cholangiocellular carcinoma cell line (KMCH-2) that shows the features of hepatocellular carcinoma or cholangiocellular carcinoma under different growth conditions. J Hepatol 24: 413–422. doi:10.1016/S0168-8278(96)80161-9. PubMed: 8738727.
18. Yano H, Iemura A, Haramaki M, Ogasawara S, Takayama A et al. (1999) Interferon alfa receptor expression and growth inhibition by interferon alfa in human liver cancer cell lines. Hepatology 29: 1708–1717. doi:10.1002/hep.105290624. PubMed: 10347112.
19. Yano H, Kojoj M, Nakashima T (1986) A new human hepatocellular carcinoma cell line (KYN-1) with a transformation to adenocarcinoma. In Vitro Cell Dev Biol 22: 637–646. doi:10.1007/BF02623477. PubMed: 2430933.
20. Yano H, Maruwi M, Murakami T, Fukuda K, Ito Y et al. (1988) A new human pleomorphic hepatocellular carcinoma cell line, KYN-2. Acta Pathol Jpn 38: 955–966. PubMed: 2854782.
21. Hisaka T, Yano H, Ogasawara S, Momosaki S, Nishida N et al. (2004) Interferon-con1 suppresses proliferation of liver cancer cells in vitro and in vivo. J Hepatol 41: 782–789. doi:10.1016/j.jhep.2004.07.012. PubMed: 15519651.
22. Takemoto Y, Yano H, Momosaki S, Ogasawara S, Nishida N et al. (2004) Antiproliferative effects of interferon-alphaCon1 on ovarian clear cell adenocarcinoma in vitro and in vivo. Clin Cancer Res 10: 7418–7426. doi:10.1158/1078-0432.CCR-04-0279. PubMed: 15534119.
23. Bailon P, Paileroni A, Schaffer CL, Spence CL, Fung WJ et al. (2001) Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug Chem 12: 195–202. doi:10.1021/ bc000082g. PubMed: 11326860.
24. Bosman FT, Carneiro F, Hruban RH, Theise ND (2010) WHO Classification of Tumours of the Digestive System (4th Revised edition). Lyon, France, IARC Press. pp. 225-227.

25. Nagano H, Miyamoto A, Wada H, Ota H, Marubashi S et al. (2007) Interferon-alpha and 5-fluorouracil combination therapy after palliative hepatic resection in patients with advanced hepatocellular carcinoma, portal venous tumor thrombus in the major trunk, and multiple nodules. Cancer 110: 2493–2501. doi:10.1002/cncr.23033. PubMed: 17941012.

26. Gillespie G, Carter WA (1981-1982) Species specificity of interferon. Tex Rep Biol Med 41: 37-42. PubMed: 6184826.

27. Hlatky L, Hahnfeldt P, Folkman J (2002) Clinical application of antiangiogenic therapy: microvesSEL density, what it does and doesn't tell us. J Natl Cancer Inst 94: 883-893. doi:10.1093/jnci/94.12.883. PubMed: 12072542.

28. Kojiro S, Yano H, Ogasawara S, Momosaki S, Takemoto Y et al. (2006) Antiproliferative effects of 5-fluorouracil and interferon-alpha in combination on a hepatocellular carcinoma cell line in vitro and in vivo. J Gastroenterol Hepatol 21: 129–137. doi:10.1111/j.1440-1746.2005.04154.x. PubMed: 1670624.

29. Dinney CP, Bielenberg DR, Perrotte P, Reich R, Eve BY et al. (1998) Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration. Cancer Res 58: 808–814. PubMed: 9485039.

30. Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE et al. (2008) Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 359: 2429–2441. doi:10.1056/NEJMoa0707615. PubMed: 19052126.

31. Lok AS, Everhart JE, Wright EC, Di Bisceglie AM, Kim HY et al. (2011) Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology 140: 840–849. doi:10.1053/j.gastro.2010.11.050. PubMed: 21129375.

32. Bruix J, Poynard T, Colombo M, Schiff E, Burak K et al. (2011) Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C. Gastroenterology 140: 1990–1999. doi:10.1053/j.gastro.2011.03.010. PubMed: 21419770.

33. Nishiguchi S, Tamori A, Kubo S (2005) Effect of long-term postoperative interferon therapy on intrahepatic recurrence and survival rate after resection of hepattis C virus-related hepatocellular carcinoma. Intervirology 48: 71–75. doi:10.1159/000082098. PubMed: 15785093.